Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in acutely psychotic adults with schizophrenia
NCT02969382Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing SEP-363856 with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 4 weeks. Started Dec 2016; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02969382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969382.